| Drug Name: | Gatifloxacin (112811-59-3) |
|---|---|
| PubChem ID: | 5379 |
| SMILES: | CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F |
| InchiKey: | XUBOMFCQGDBHNK-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Infective Agents |
| Molecular Weight (dalton) | : | 375.4 |
| LogP | : | 1.9804 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 83.8 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Amiodarone (1951-25-3) | Arrhythmia | Additive | Not established | Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin |
| Procainamide (51-06-9) | Torsade De Pointes | Antagonistic | The probable reason for the interaction is that gatifloxacininhibit the secretion of unchanged procainamide by the kidney tubules via renal drug transporters. It also appears to inhibit the secretion of N-acetylprocainamide | Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin |
| Warfarin (81-81-2) | Bleeding | Antagonistic | Uncertain. It is not clear what factors might have been responsible in those cases where the effects of the anticoagulants were increased | Drug interaction |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category